Rectal carcinoma

This phase 2 trial is testing whether a combination of two immunotherapy drugs, botensilimab and balstilimab, can completely eliminate early-stage rectal cancer in people whose tumors are microsatellite stable (MSS). Participants receive one infusion of botensilimab followed by b…

This trial is testing a combination of local tumor removal and chemoradiotherapy (radiation plus capecitabine chemotherapy) in people with early-stage rectal cancer located low in the rectum. The goal is to see if this approach can effectively treat the cancer while avoiding the …

This study is for people with locally advanced rectal cancer. It tests whether using MRI scans early after chemotherapy can help doctors choose the best next step: surgery or more chemo with radiation. The goal is to improve cancer control and reduce side effects. About 1,075 par…

This trial investigates whether giving a higher dose of radiotherapy can safely control locally recurrent rectal cancer that cannot be surgically removed. Around 30 adults with this condition will receive either stereotactic body radiotherapy or hyperfractionated chemo-reirradiat…

This study tests whether two immunotherapy drugs, botensilimab and balstilimab, can shrink or eliminate rectal tumors in people with a specific type of rectal cancer (MMRp/MSS) that usually doesn't respond to immunotherapy alone. About 40 adults with stage II or III rectal cancer…

This study tests whether adding an immunotherapy drug (sintilimab) to short-course radiation and chemotherapy can improve long-term survival in people with a common type of locally advanced rectal cancer (MSS type). About 130 adults aged 18-75 with stage II/III rectal cancer will…

This phase 3 trial is testing whether adding the immunotherapy drug pucotenlimab to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced rectal cancer. About 556 participants will be randomly assigned to receive either CAPOX plus puco…

This phase II trial is testing whether a high-precision radiation technique called stereotactic body radiation therapy (SBRT) can help control locally recurrent rectal cancer that cannot be surgically removed. The study will enroll 40 adults aged 18-75 with unresectable tumors an…

This study tests whether combining targeted radiation (SBRT) with an immunotherapy drug (PD-1 antibody) can help people whose rectal cancer has returned and cannot be surgically removed. About 31 adults with a specific type of colorectal cancer will receive the treatment and be f…

This phase II trial tests whether giving zanidatamab before surgery can shrink tumors in people with HER2+ colorectal cancer. About 38 participants will receive the drug intravenously, then undergo surgery. The study measures how much the tumor regresses and whether cancer return…

This early-phase trial tests whether a short course of radiation followed by chemotherapy can shrink advanced rectal tumors enough to avoid surgery. About 25 people with stage II or III rectal cancer will receive the treatment. The goal is to preserve the rectum and improve quali…

This study is for people with a certain type of locally advanced rectal cancer (pMMR/MSS) that often doesn't respond well to immunotherapy alone. The trial combines an immunotherapy drug (serplulimab) with chemotherapy (CAPEOX) and an anti-inflammatory drug (celecoxib) to see if …

This phase 3 trial is testing whether a powerful chemotherapy combination (mFOLFOXIRI plus bevacizumab) can be used instead of standard chemoradiation before surgery for people with high-risk locally advanced rectal cancer. The goal is to see if this approach can reduce the chanc…

This phase 3 trial tests whether adding modulated electro-hyperthermia (mEHT) to standard treatment helps shrink locally advanced rectal cancer. About 126 adults will receive either standard therapy alone or with mEHT twice a week for six weeks. The goal is to see if the heat-bas…

This phase 2 trial tests whether adding an immunotherapy drug (PD-1 antibody) and a blood vessel blocker (bevacizumab) to standard short-course radiotherapy and chemotherapy can improve outcomes for people with a common type of locally advanced rectal cancer (pMMR/MSS). About 86 …

This clinical trial is testing whether adding the immunotherapy drug tislelizumab to standard chemoradiation helps people with locally advanced rectal cancer. The study involves 375 participants who will receive either the combination or standard treatment alone. The main goal is…

This study is testing whether a new type of CT scanner, called photon-counting detector CT (PCD-CT), can determine how far rectal cancer has grown as accurately as MRI. About 200 adults with rectal cancer will get both a standard MRI and the new CT scan, and doctors will compare …

This study tests whether a special algorithm called PAGODA can reduce unplanned delays during FOLFOX chemotherapy for gastrointestinal cancers like colon, stomach, and esophageal cancer. About 420 participants will be randomly assigned to either standard care or the algorithm-gui…

This phase 2 trial tests whether a vaginal DHEA suppository can safely improve vaginal health in 25 women who had radiation for gynecologic, anal, or rectal cancer. Radiation often causes dryness, burning, and pain, similar to menopause. DHEA is a hormone replacement that may hel…

This study compares a bowel management program that includes a retrograde rectal enema (RRE) against standard medical care (fiber, loperamide, pelvic floor therapy) for people with low anterior resection syndrome (LARS) after rectal cancer surgery. Researchers will enroll 80 adul…

This study looks at whether having a healthcare provider directly contact close relatives of people with newly diagnosed colorectal cancer leads to more genetic testing than having the patient share the information themselves. About 4,186 patients and their relatives will take pa…

This study follows 430 people with stage I-IV rectal cancer to measure their quality of life after surgery. Participants fill out questionnaires about their well-being and daily function. The goal is to learn how surgery impacts patients over time, not to test a new treatment.

This study aims to find biomarkers in tumor tissue that can predict whether a patient with locally advanced rectal cancer will resist neoadjuvant chemoradiotherapy. About half of patients do not respond well to this treatment, and identifying these patients beforehand could help …

This early-phase trial is testing two new antibody fragments that are designed to attach to a sugar molecule found on many solid tumors. The fragments are labeled with a radioactive tracer so they can be seen on PET/CT scans. The study aims to see where these fragments go in the …